However, following the administration of a BRAFi in patients with melanoma, tumor biopsies demonstrated a higher infiltration of both CD4+ and CD8+ T lymphocytes within 2 weeks of treatment initiation [10,21]. This evidence concerns the gene CD8A and neoplasm.